Equity · Healthcare
JBIO
Jade Biosciences, Inc. · NasdaqCM
The line runs $15.25 on 10 June through $21 on 17 July, on a scale from $15.0 to $25.0. Days the market did not trade hold the previous close, flat.
The chart above plots the price of JBIO over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 26 sessions over that window: $15.25 on 10 June 2026 through $21 on 17 July 2026.
Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 8, 2026
JBIO insider trades
JBIO has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 6 October 2025.
Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
JBIO reported financials
JBIO reported net income of −$127.4M for the fiscal year ended 31 Dec 2025.
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
JBIO earnings
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
JBIO institutional holders
11 of the 45 institutional funds we track reported a JBIO position for the quarter ended 30 Jun 2026 — a combined $95.9M; the latest of those filings landed 02 Sep 2026.
Showing the 10 largest of 11 reported positions. The figures above count all of them.
Source: SEC EDGAR 13F filings
JBIO fails-to-deliver
On 03 Aug 2026, 49,666 shares of JBIO failed to deliver (about $981K).
Source: SEC fails-to-deliver (CNS) data